Clinical Trials Sponsored by UBI Pharma Inc.

Total 2393 results

Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA)

United States, Poland
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Lymphoma | Advanced Cancer | Refractory Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Moldova, Republic of
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
Astellas Pharma Inc
Astellas Pharma Global Development, Inc.

Completed

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Solid Tumors

United States, Japan, Korea, Republic of, Taiwan
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Astellas Pharma Global Development, Inc.

Completed

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Healthy Volunteers | Pharmacokinetics of ASP1941

United States
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Claudin 18.2 (CLDN18.2) Positive Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | FLT3-mutated Acute Myeloid Leukemia

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

United States, Canada, Germany, Italy, Spain, United Kingdom, France
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Age-Related Macular Degeneration | Geographic Atrophy

United States, Italy, Latvia, France, Israel, Germany, Spain, Hungary, Brazil, Canada, Argentina, Colombia, Croatia, Australia, Austria, Belgium, Czechia
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Advanced Cancer | Advanced Malignancies

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

Invasive Aspergillosis | Invasive Mucormycosis

United States, Belgium, Spain
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

United States
Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause (Skylight 1)

Hot Flashes

United States, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Renal Impairment | Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Peanut Allergy

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Peanut Allergy

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Acute Myeloid Leukemia (AML)

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Tumors | Incurable Platinum Refractory Germ Cell Tumors

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Canada, United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Healthy | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

Registry of Patients Treated With Systemic Mold-Active Triazoles

Invasive Fungal Infection

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PLUS)

Overactive Bladder | Benign Prostatic Hyperplasia

United States, Canada, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (FAST)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Bulgaria, Czechia, Germany, Latvia, Russian Federation, Ukraine
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Fibromyalgia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Poland, Czechia, Bulgaria, Hungary, Mexico
Astellas Pharma Global Development, Inc.

Terminated

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Non-hematologic Malignancies | Pharmacokinetics of ASP9853

United States
Astellas Pharma Global Development, Inc.

Completed

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, Italy
Astellas Pharma Global Development, Inc.

Terminated

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy (PDPN)

United States
Astellas Pharma Global Development, Inc.

Completed

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Advanced Solid Tumors

Germany, Czechia, United States, Brazil, Poland, Singapore, Thailand
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

Healthy Subjects | Pharmacokinetics of ASP4058 | Food Effect of ASP4058

United States
gicare Pharma Inc.
Algorithme Pharma Inc; JSS Medical Research Inc.

Completed

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

Pain | Cancer | Colonic Diseases

United States, Canada
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Approved for marketing

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration-Resistant Prostate Cancer
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
ImmunoRx Pharma Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Healthy Participants

Netherlands
Telios Pharma, Inc.

Recruiting

A Study Of TL-925 For The Treatment of AC

Allergic Conjunctivitis

United States

3

Subscribe